NASDAQ Composite ended the session with Moderna jumping 5.54% to $123.76 on Tuesday, following last session’s upward trend. NASDAQ Composite rose 0.23% to $13,066.03, following last session’s downward trend on what was a somewhat positive trend exchanging session today.
Moderna today’s close was $123.76, 44.23% under its 52-week high of $178.50.
News about Moderna today
According to today’s article on Business Insider, "With the Oxford and Pfizer vaccines currently being rolled out and the Moderna vaccine becoming the third COVID jab approved in the UK, employers are now one step closer to getting their businesses back up and running again. "
According to today’s article on Business Insider, "The exception is the Moderna vaccine, which can be stored at higher temperature than some of the others, like Pfizer-BioNtech, Maxson said."
Moderna’s sales growth is 1986.4% for the current quarter and 19117.5% for the next. The company’s growth estimates for the current quarter and the next is 18.9% and 660%, respectively.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s last day, last week, and last month’s average volatility was a positive 4.00%, a positive 1.01%, and a negative 1.43%, respectively.
Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 7.65%, 7.21%, and 8.47%, respectively.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $123.76 at 16:56 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.91.
Moderna’s Moving Average
Moderna’s value is below its 50-day moving average of $131.70 and way above its 200-day moving average of $86.18.
Previous days news about Moderna
According to FX Empire on Saturday, 9 January, "Approval of the Moderna Inc. vaccine, however, limited the impact of planned containment measures in the week."
According to FX Empire on Saturday, 9 January, "Early in the week, the EU’s approval of the Moderna Inc. vaccine delivered support to the European majors."
According to Bloomberg Quint on Monday, 11 January, "The move, announced by Biden’s office Friday and supported by a group of Democratic governors, represents a gamble by the incoming administration that there will be enough vaccine available to ensure second shots after 21 days for the Pfizer-BioNTech vaccine, and 28 days for the Moderna shot."
According to Bloomberg Quint on Monday, 11 January, "The move, announced by Biden’s office Friday and supported by a group of Democratic governors, represents a gamble by the incoming administration that there will be enough supply available to ensure timely second shots for both the Pfizer-BioNTech and Moderna vaccines."
According to MarketWatch on Monday, 11 January, "The U.S. counted at least 208,338 cases on Sunday, and German partner BioNTech SE , and one developed by Moderna Inc. , with much fanfare in December."